Dataset Information

Plasma multi-omics identify early pathogenesis and biomarkers of SCD post-AMI

ABSTRACT: Early identification and treatment of Sudden Cardiac Death (SCD) post-myocardial infarction (MI) are currently limited by unclear warning indicators and elusive pathogenesis. Here, we constructed a comprehensive multi-omics blood atlas in the acute phase of AMI from 55 pairs of SCD patients and matched survivors, confirmed immune dysregulation and metabolic disorders as the biological hubs leading to post-MI SCD. Targeted proteome quantification identified a TOP4 protein-based biomarker panel, which were validated by internal and external cohorts, and confirmed a superior early prediction power of SCD to traditional clinical risk models. Further interventions targeting complement factor D (CFD) suggested a potential therapeutic strategy for high-risk MI. Our study provided valuable knowledge about the molecular changes and pathogenesis of SCD, shed light on accurate risk stratification and potential therapeutic targets in high SCD-risk MI.

ORGANISM(S): Homo sapiens

PROVIDER: GSE221740 | GEO | 2024/12/31

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Pregnancy in Sickle Cell Disease (SCD) women is associated to increased risk of clinical and obstetrical complications. Placentas from SCD pregnancies can present increased abnormal findings, which may lead to placental insufficiency, favoring adverse perinatal outcome. These placental abnormalities are well known and reported, however little is known about the molecular mechanisms, such as epigenetics. Thus, our aim was to evaluate the DNA methylation profile in placentas from women with SCD (HbSS and HbSC genotypes), compared to uncomplicated controls (HbAA). We included in this study 11 pregnant women with HbSS, 11 with HbSC and 21 with HbAA genotypes. Illumina Methylation EPIC BeadChip was used to assess the whole placental DNA methylation. Pyrosequencing was used for array data validation and qRT-PCR was applied for gene expression analysis. Our results showed high frequency of hypermethylated CpGs sites in HbSS and HbSC groups with 73.5% and 76.2% respectively, when compared with the control group. Differentially methylated regions (DMRs) also showed an increased hypermethylation status for the HbSS (89%) and HbSC (86%) groups, when compared with the control group methylation data. DMRs were selected for methylation validation (4 DMRs-HbSS and 3 DMRs the HbSC groups) and after analyses three were validated in the HbSS group, and none in the HbSC group. The gene expression analysis showed differential expression for the PTGFR (-2.97-fold) and GPR56 (3.0-fold) genes in the HbSS group, and for the SPOCK1 (-2.40-fold) and ADCY4 (1.80-fold) genes in the HbSC group. Taken together, these data strongly suggest that SCD (HbSS and HbSC genotypes) can alter placental DNA methylation and lead to gene expression changes. These changes possibly contribute to abnormal placental development and could impact in the clinical course, especially for the fetus, possibly leading to increased risk of abortion, fetal growth restriction (FGR), stillbirth, small for gestational age newborns and prematurity.

Dataset Information

Plasma multi-omics identify early pathogenesis and biomarkers of SCD post-AMI

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets